Key Developments: Annidis Corp (RHA.V)

RHA.V on TSX Venture Exchange

0.28CAD
30 Oct 2014
Price Change (% chg)

-- (--)
Prev Close
$0.28
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,228
52-wk High
$0.35
52-wk Low
$0.20

Search Stocks

Latest Key Developments (Source: Significant Developments)

Annidis Corp announces China FDA approval of its RHA Multi-Spectral Imaging Technology and receives purchase order
Wednesday, 9 Jul 2014 08:00am EDT 

Annidis Corp:Receives notice that China Food and Drug Administration (CFDA) has approved company's RHA Gold Multi-Spectral Imaging instrument to be sold to eye-care professionals in Chinese market.Says it has received purchase order for twenty (20) RHA instruments from its Chinese distribution partner YIMAI Technology International Company Limited.  Full Article

Annidis Corp announces private placement of $1,000,000 secured promissory note
Wednesday, 28 May 2014 06:07pm EDT 

Annidis Corp:Completes private placement of secured promissory note with insider of corporation whereby corporation will issue a $1,000,000 secured promissory note.Note has three-year term and bears interest at a rate of 10 pct per annum compounded monthly and payable at maturity.Note will be secured by a general security agreement over the assets of the Corporation, which security shall be subordinated to all existing charges against the assets of the Corporation.Proceeds from financing will be used by corporation for general working capital purposes.  Full Article

Annidis Corp completes vertical short-form amalgamation with wholly-owned subsidiary
Thursday, 2 Jan 2014 05:30pm EST 

Annidis Corp:Says effective Jan. 1, it has completed a vertical short-form amalgamation pursuant to the Business Corporations Act (Ontario) with its wholly owned operating subsidiary Annidis Health Systems Corp. (AHSC).Says pursuant to the amalgamation, all of the issued and outstanding shares of AHSC will be cancelled and the assets, obligations and liabilities of AHSC will be assumed by Annidis.Says No securities of Annidis will be issued in connection with the amalgamation and the share capital of the Annidis will remain unchanged.Says the amalgamation of Annidis and AHSC has been undertaken in order to simplify the corporate structure of Annidis and to reduce administrative costs.  Full Article

Annidis Corp Closes $5,000,000 Private Placement Financing
Friday, 4 Oct 2013 08:30am EDT 

Annidis Corp announced that it has closed its previously announced $5,000,000 private placement of common shares (the Financing) with Yimai Technology International Company Limited (YIMAI), a Hong Kong company that markets and distributes ophthalmology products in China. The Financing consisted of the issuance of an aggregate of 27,965,379 common shares to YIMAI for total consideration of $5,000,000. All common shares issued pursuant to the Financing are subject to a statutory hold period of four months and one day from the date of closing. Of these 27,965,379 common shares, 7,132,046 will be held in escrow by Annidis (the Escrowed Shares) and will be released to YIMAI on the basis of one Escrowed Share for each (approximately) 3.26 common shares which are issued upon exercise of certain of the Company's other outstanding convertible securities (the Convertible Securities) on or before September 30, 2016.  Full Article

Annidis Corp Announces Closing Of Its Promissory Note Financing And Completion Of International Distribution Agreement
Wednesday, 26 Jun 2013 07:00am EDT 

Annidis Corp announced that it closed its $3,000,000 promissory note financing announced on November 29, 2012. The Company also announced its subsidiary completed a distribution agreement with Yimai Technology International Company Limited (YIMAI), a Hong Kongcompany which through its affiliates distributes ophthalmology products in China.YIMAI subscribed for $1,000,000 of the promissory note offering which along with $333,313 of additional commitments from third parties completes the offering. Each lender received one common share purchase warrant for every one dollar of principal loaned to Annidis. Each Warrant may be exercised at a price of $0.40 per common share for a period of three years from the date of issuance, subject to early termination or expiry provisions. The proceeds from the Financing will be used by Annidis for general working capital purposes including accelerating manufacturing. Annidis Health Systems Corp., a wholly-owned subsidiary of Annidis, also entered into a distribution agreement with YIMAI to provide them exclusive distribution rights of Annidis products in the People's Republic of China, including Hong Kong and Macau. YIMAI, through its affiliate Shenzhen New Industries Material Of Ophthalmology Co. Ltd., markets and distributes ophthalmology products in China through its 13 nationwide offices. The term of the agreement is six years.  Full Article

Annidis Corp Announces Financing Arrangements And An International Distribution Agreement
Monday, 17 Jun 2013 10:22am EDT 

Annidis Corp announced that it has entered into a financing and distribution agreement with Yimai Technology International Company Limited (YIMAI), a Hong Kongcompany. YIMAI, through its affiliate Shenzhen New Industries Material Of Ophthalmology Co. Ltd., markets and distributes ophthalmology products in China. Following the completion of this transaction, subject to regulatory approval, Annidis will receive gross proceeds of $6 million. These funds will be used to increase manufacturing capabilities and continue to build on its current sales initiatives.  Full Article

No consensus analysis data available.
Search Stocks